Press Releases

TOLEDO, OHIO and TEL AVIV, ISRAEL – BUSINESSWIRE—SEPTEMBER 8, 2022—NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, and InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for treatment of carotid artery disease and prevention of stroke, announced today that they have entered into a strategic outsourcing… Read More

– Generated 47.8% growth in CGuard™ revenue year-over-year – – Delivered several presentations at LINC 2022 featuring CGuard™ EPS, including a successful live case transmission – – Announced that endovascular pioneer Dr. Juan Parodi has agreed to act as strategic advisor to the company – — Management to Host Investor Conference Call Today, August 9th,… Read More

-Conference call and webcast to be held at 8:30 a.m. EDT-  Tel Aviv, Israel— August 1, 2022 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report second quarter 2022 financial results on Tuesday, August… Read More

Credited with performing the first ever endovascular repair procedure in 1990 Tel Aviv, Israel — July 14, 2022 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced the appointment of endovascular pioneer Dr. Juan Parodi as a strategic advisor to the Company. Marvin Slosman,… Read More

Successful live case transmission again demonstrated CGuard’s™ differentiated patient protection features and ease of use Tel Aviv, Israel — June 9, 2022 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today provided the following highlights from multiple presentations and live case transmission, all featuring its… Read More

 Live case transmission designed to demonstrate ease-of-use and exceptional patient safety features of CGuard™ Embolic Prevention System (EPS)  Tel Aviv, Israel — June 2, 2022 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced that the company will participate in the Leipzig Interventional Course… Read More

– 20% growth in CGuard™ revenue Year-over-Year – – C-Guardian FDA IDE Trial Completes First European Enrollment – – Held Key Opinion Leader (KOL) Webinar on Carotid Artery Disease Management and Stroke Prevention, highlighting CGuard™ clinical advantages – – European logistics hub established with BOMI Group –for direct market access as well as establishing the commercial… Read More

-Earnings Conference Call to be held Tuesday, May 10, 2022, at 8:30 a.m. ET- Tel Aviv, Israel— April 28, 2022 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report first quarter 2022 financial results… Read More

Tuesday, March 22nd @ 2 p.m. ET Tel Aviv, Israel— March 16, 2022 – InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today that it will host a Key Opinion Leader (KOL) webinar on its CGuard Stent… Read More

– CGuard™ Revenue Generated 87.5% growth over Q4’20 and 55.9% Year-over-Year –- – Published CGuard Clinical trial results in Journals of the American College of Cardiology – – Established Reimbursement Approval for CGuard from the French National Authority – – CGuard Included as Carotid Stent Treatment Option in National Institute of Neurological Disorders and Stroke… Read More